Audit/research project for follow-up cystoscopy superficial bladder cancer

ISRCTN ISRCTN24647129
DOI https://doi.org/10.1186/ISRCTN24647129
Protocol serial number SUPBLACAN
Sponsor NHS R&D Regional Programme Register - Department of Health (UK)
Funder NHS Executive Northern and Yorkshire (UK)
Submission date
23/01/2004
Registration date
23/01/2004
Last edited
24/10/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Mr R Hall
Scientific

Freeman Hospital
Newcastle
NE7 7DN
United Kingdom

Study information

Primary study designInterventional
Study designRandomised controlled trial
Secondary study designRandomised controlled trial
Study type Participant information sheet
Scientific titleAudit/research project for follow-up cystoscopy superficial bladder cancer
Study objectives1. To conduct an audit of a new programme of cystoscopic follow-up for patients with Ta. T1 bladder carcinoma.
2. To conduct a randomised comparison of:
2.1. Mitocytin-C versus epirubicin as single intravesical instillations at the time of diagnosis to evaluate relative efficacy in prevention of recurrent bladder cancer
2.2. A single instillation of intravesical chemotherapy (MMC or Epi) versus five instillations (to be given at the time of each follow-up cystoscopy for 1 year) to determine the relative efficacy in reducing tumour recurrence in medium risk Ta.T1 bladder cancer.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedCancer (neoplasms): Bladder (superficial)
InterventionNot provided at time of registration
Intervention typeDrug
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Mitocytin-C versus Epirubicin
Primary outcome measure(s)

1.1 Number of unplanned incidents (return with symptoms, need for unscheduled cystoscopies or tumour resections).
1.2 Tumour recurrence rate and number of patients progressing to muscle invasion at 2 years.
iii. Inter-hospital variation of type of cystoscopy, anaesthetic, out-patient, day case, in-patient mix and cost of same.
2. Recurrence rate and progression to muscle invasion at 2 years.

Key secondary outcome measure(s)

Not provided at time of registration

Completion date15/05/1997

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Key inclusion criteriaNot provided at time of registration
Key exclusion criteriaNot provided at time of registration
Date of first enrolment16/05/1994
Date of final enrolment15/05/1997

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

Freeman Hospital
Newcastle
NE7 7DN
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes

Editorial Notes

24/10/2019: No publications found. All search options exhausted.